The DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.
New progestagens for contraceptive use
Abstract
The progestins have different pharmacologic properties depending upon the parent molecule, usually testosterone or progesterone (P), from which they are derived. Very small structural changes in the parent molecule may induce considerable differences in the activity of the derivative. In hormonal contraceptives, progestins represent the major agent designed for suppressing ovulation and are used in combination with estrogen (E) usually ethinyl-estradiol (EE). The development of new generations of progestins with improved selectivity profiles has been a great challenge. Steroidal and nonsteroidal progesterone receptor (PR) agonists have been synthesized as well, although the latter are still in a very early stage of development. Several new progestins, have been synthesized in the last two decades. These include dienogest (DNG), drospirenone (DRSP), Nestorone (NES), nomegestrol acetate (NOMAc) and trimegestone (TMG). These new progestins have been designed to have no androgenic or estrogenic actions and to be closer in activity to the physiological hormone P. DRSP differs from the classic progestins as it is derived from spirolactone. It is essentially an antimineralocorticoid steroid with no androgenic effect but a partial antiandrogenic effect. The antiovulatory potency of the different progestins varies. TMG and NES are the most potent progestins synthesized to date, followed by two of the older progestins, keto-desogestrel (keto-DSG) and levonorgestrel (LNG). The new molecules TMG, DRSP and DNG also have antiandrogenic activity. Striking differences exist regarding the side effects among the progestins and the combination with EE leads to other reactions related to the E itself and whether the associated progestin counterbalances, more or less, the estrogenic action. The 19-norprogesterone molecules and the new molecules DRSP and DNG are not androgenic and, therefore, have no negative effect on the lipid profile. Given their pharmacological properties, it is likely that the new progestins may have neutral effects on metabolic or vascular risks. However, this hypothesis must be confirmed in large clinical trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Arzneimittelforschung: Erstanwendung am Menschen in der Phase I
Miletzki, B., & Gleiter, C. H. (2005) · Bundesgesundheitsblatt Gesundheitsforsch.Gesundheitsschutz · doi:10.1007/s00103-005-1024-7 · Cited by 9,355
Breast cancer and hormone-replacement therapy in the Million Women Study
(2003) · The Lancet · doi:10.1016/s0140-6736(03)14065-2 · Cited by 2,993
Classification and pharmacology of progestins
Schindler, A. E., Campagnoli, C., Druckmann, R., Huber, J., Pasqualini, J. R., Schweppe, K. W., & Thijssen, J. H. H. (2003) · Maturitas · doi:10.1016/j.maturitas.2003.09.014 · Cited by 745
Oral Contraceptives and the Risk of Breast Cancer
Marchbanks, P. A., McDonald, J. A., Wilson, H. G., Folger, S. G., Mandel, M. G., Daling, J. R., Bernstein, L., Malone, K. E., Ursin, G., Strom, B. L., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa013202 · Cited by 532
Third generation oral contraceptives and risk of venous thrombosis: meta-analysis
Kemmeren, J. M., Algra, A., & Grobbee, D. E. (2001) · BMJ · doi:10.1136/bmj.323.7305.131 · Cited by 455
Oral contraceptives and the risk of breast cancer*
(2003) · Obstetrics & Gynecology · doi:10.1097/00006250-200304000-00031 · Cited by 431
Fournier, A., Berrino, F., Riboli, E., Avenel, V., & Clavel‐Chapelon, F. (2005) · International Journal of Cancer · doi:10.1002/ijc.20710 · Cited by 403
Mellick, R. S., Mahler, R. F., & Hughes, B. P. (1962) · The Lancet · doi:10.1016/s0140-6736(62)92145-1 · Cited by 390
Drospirenone: pharmacology and pharmacokinetics of a unique progestogen
Krattenmacher, R. (2000) · Contraception · doi:10.1016/s0010-7824(00)00133-5 · Cited by 376
Giangrande, P. H., & McDonnell, D. P. (1999) · PubMed · Cited by 339
Research works printed but not linked: 17
- Bouali, 2001, Gynecol Endocrinol, 15, 48, 10.1080/gye.15.1.48.55 · doi:10.1080/gye.15.1.48.55
- Catherino, 1993, Br J Cancer, 67, 945, 10.1038/bjc.1993.175 · doi:10.1038/bjc.1993.175
- Duc, 1995, Arzneimittelforschung, 45, 70
- Erkkola, 2005, Acta Obstet Gynecol Scand, 84, 207, 10.1111/j.0001-6349.2005.00759.x · doi:10.1111/j.0001-6349.2005.00759.x
- Fotherby, 1990, Contraception, 41, 533, 10.1016/0010-7824(90)90062-Z · doi:10.1016/0010-7824(90)90062-z
- Giangrande, 1999, Recent Prog Horm Res, 54, 291
- Grubb, 2003, Steroids, 68, 921, 10.1016/j.steroids.2003.09.001 · doi:10.1016/j.steroids.2003.09.001
- Maillard-Salin, 2000, Int J Pharm, 199, 29, 10.1016/S0378-5173(00)00357-4 · doi:10.1016/s0378-5173(00)00357-4
- Massai, 2001, Contraception, 64, 369, 10.1016/S0010-7824(01)00259-1 · doi:10.1016/s0010-7824(01)00259-1
- Musgrove, 1991, Mol Cell Biol, 11, 5032
- Nelson, 1996, J Reprod Med, 41, 391
- Noe, 1993, Contraception, 48, 548, 10.1016/0010-7824(93)90117-P · doi:10.1016/0010-7824(93)90117-p
- Odlind, 2002, Acta Obstet Gynecol Scand, 81, 482
- Oelkers, 1995, J Clin Endocrinol Metab, 80, 1816
- Oettel, 2001, Drugs Today, 37, 3
- Paris, 1983, Arzneimittelforschung, 33, 710
- Teichmann, 2003, Climacteric, 6, 17
Cited by
Sex hormones, appetite and eating behaviour in women
Hirschberg, A. L. (2012) · Maturitas · doi:10.1016/j.maturitas.2011.12.016 · Cited by 338
[Ca2+]i signalling in sperm — making the most of what you've got
Publicover, S., Harper, C. V., & Barratt, C. (2007) · Nature Cell Biology · doi:10.1038/ncb0307-235 · Cited by 292
Sitruk-Ware, R., & Nath, A. (2013) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2012.09.004 · Cited by 247
Medical treatment of endometriosis-related pain
Vercellini, P., Buggio, L., Frattaruolo, M. P., Borghi, A., Dridi, D., & Somigliana, E. (2018) · Best Practice & Research Clinical Obstetrics & Gynaecology · doi:10.1016/j.bpobgyn.2018.01.015 · Cited by 188
Steroidal contraceptives: effect on carbohydrate metabolism in women without diabetes mellitus
Lopez, L. M., Grimes, D. A., & Schulz, K. F. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006133.pub5 · Cited by 166
Metadata
- Authors
- Sitruk-Ware, R.
- Venue
- Human Reproduction Update
- Publisher
- Oxford University Press (OUP)
- Published
- 2005-11-16
- Volume
- 12
- Issue
- 2
- Pages
- 169-178
- ISSN
- 1355-4786 (ISSN-L)
- 1460-2369
- OpenAlex
- W2100560126
- Cited by
- 362
- References
- 54
- FWCI
- 9.70
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: New progestagens for contraceptive use. https://app.cochat.ai/papers/10.1093/humupd/dmi046
- The paper
- Sitruk-Ware, R. (2006). New progestagens for contraceptive use. Human Reproduction Update. https://doi.org/10.1093/humupd/dmi046
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.